Piper Sandler Boosts Hims & Hers Health (NYSE:HIMS) Price Target to $35.00

Hims & Hers Health (NYSE:HIMS) had its target price increased by equities researchers at Piper Sandler from $24.00 to $35.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Piper Sandler’s price objective would suggest a potential downside of 16.40% from the stock’s current price.

A number of other research firms also recently weighed in on HIMS. Canaccord Genuity Group increased their target price on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Citigroup upped their price target on shares of Hims & Hers Health from $25.00 to $27.00 and gave the company a “sell” rating in a research report on Tuesday. Bank of America raised their price objective on shares of Hims & Hers Health from $18.00 to $21.00 and gave the stock an “underperform” rating in a report on Thursday, February 20th. TD Cowen reaffirmed a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, Needham & Company LLC lifted their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $34.47.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $41.87 on Tuesday. The business has a 50-day simple moving average of $35.89 and a two-hundred day simple moving average of $26.36. The firm has a market cap of $9.15 billion, a price-to-earnings ratio of 95.15 and a beta of 1.35. Hims & Hers Health has a fifty-two week low of $11.20 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. As a group, research analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $33.56, for a total value of $68,932.24. Following the completion of the transaction, the insider now directly owns 184,947 shares in the company, valued at $6,206,821.32. This represents a 1.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Soleil Boughton sold 268,932 shares of Hims & Hers Health stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now owns 169,803 shares in the company, valued at approximately $4,712,033.25. The trade was a 61.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,097,578 shares of company stock valued at $38,080,320 over the last 90 days. Company insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently bought and sold shares of HIMS. B. Riley Wealth Advisors Inc. bought a new stake in shares of Hims & Hers Health in the fourth quarter worth about $200,000. Mackenzie Financial Corp increased its stake in Hims & Hers Health by 44.6% in the 4th quarter. Mackenzie Financial Corp now owns 29,096 shares of the company’s stock worth $704,000 after acquiring an additional 8,977 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Hims & Hers Health during the 4th quarter worth approximately $99,000. Neo Ivy Capital Management boosted its position in shares of Hims & Hers Health by 145.4% during the 4th quarter. Neo Ivy Capital Management now owns 166,734 shares of the company’s stock valued at $4,031,000 after acquiring an additional 98,798 shares during the last quarter. Finally, PharVision Advisers LLC bought a new position in shares of Hims & Hers Health during the 4th quarter valued at approximately $234,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.